雷珠单抗联合中药治疗黄斑病变的研究进展
|
摘要
黄斑病变是一种常见的以视力减退为主要症状的眼部疾病,近年来发病率呈增长态势。临床上治疗黄斑病变常使用血管内皮生长因子抑制剂雷珠单抗,另外应用中药来缓解和改善黄斑病变也有广泛的研究。笔者发现,多项研究显示雷珠单抗和中药联合应用治疗黄斑病变具有良好效果。本文回顾近几年文献,对雷珠单抗联合中药治疗黄斑病变做出总结,并提供进一步研究思路。
Macular degeneration is a common ocular disease characterized by loss of vision.The incidence of this disease shows an increasing trend recently. Ranicizumab, a vascular endothelial growth factor(VEGF) inhibitor, is often used in clinical treatment of macular disease. Besides, traditional Chinese medicine for relieving and amending macular degeneration is also extensively studied. The author found that multiple studies show that Ranicizumab in combination with traditional Chinese medical therapy on macular degeneration yield favorable effects. In light of the literature in recent years, this article made a summary on the studies involving Ranicizumab in combination with traditional Chinese medical therapy for macular degeneration, and provided further research ideas.
Macular degeneration is a common ocular disease characterized by loss of vision.The incidence of this disease shows an increasing trend recently. Ranicizumab, a vascular endothelial growth factor(VEGF) inhibitor, is often used in clinical treatment of macular disease. Besides, traditional Chinese medicine for relieving and amending macular degeneration is also extensively studied. The author found that multiple studies show that Ranicizumab in combination with traditional Chinese medical therapy on macular degeneration yield favorable effects. In light of the literature in recent years, this article made a summary on the studies involving Ranicizumab in combination with traditional Chinese medical therapy for macular degeneration, and provided further research ideas.
引文
[1]SINGER MA,AWH CC,SADDA S,et al.Horizon:an open-label extension trial of ranibizumab for choroidal neovasculariz ation secondary to age-related macular degeneration[J].Ophthalmology,2012,199(6):1175-1183.
[2]BURAK SIMSEK,AYLIN ARDAGIL AKCAKAYA,ISILAY,et al.Long-term outcomes of Ranibizumab treatment in neovascular agerelated macular degeneration[J].Int Eye Sci,2018,18(3):406-411.
[3]罗丹.黄斑变性1号方治疗渗出型年龄相关性黄斑变性的临床观察及机制研究[D].北京:北京中医药大学,2017.
[4]吴权龙,彭清华,陈向东,等.散血明目片联合雷珠单抗眼内注射治疗湿性年龄相关性黄斑变性的临床观察[J].中南药学,2016,14(3):329-332.
[5]贺凤娇,谢文军,姜尚平.益气复明汤联合雷珠单抗治疗渗出型老年性黄斑变性60例总结[J],湖南中医杂志,2017,33(10):81-83.
[6]WONG TY,FERREIRA A,HUGHES R,et al.Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization:an evidence-based systematic review[J].American Journal of Ophthalmology,2014,157(1):9-25.
[7]张红,庄曾渊.高度近视黄斑出血荧光素眼底血管造影改变与辨证论治关系的初步研究[J].中国中医眼科杂志,2007,17(4):192-196.
[8]刘彦江,张月,亢泽峰,等.加减驻景方联合雷珠单抗治疗高度近视性黄斑出血[J].国际眼科杂志,2014,14(2):313-316.
[9]刘莉,张凤梅,李昊洋.中西医结合治疗高度近视黄斑出血临床观察[J].实用中医药杂志,2017,33(12):1397-1398.
[10]闫亚红.中西医结合治疗高度近视黄斑出血临床分析[C]//江西省第十三次中西医结合中医眼科学术交流会暨赣州市医学会眼科学会第八次学术会议论文汇编,赣州:2006:15.
[11]任征,钟良玉.中药为主治疗中心性渗出性脉络膜视网膜病变[J].中国中医眼科杂志,2003,13(1):43-44.
[12]张丽,孟凡毅,朱珂珂,等.玻璃体腔注射雷珠单抗联合复方血栓通胶囊治疗中心性渗出性脉络膜视网膜病变[J].国际眼科杂志,2017,17(4):706-709.
[13]SONJA G.KARST,JAN LAMMER,CHRISTOPH MITSCH,et al.Detailed analysis of retinal morphology in patients with diabetic macular edema(DME)randomized to ranibizumab or triamcinolone treatment[J].Graefes Arch Clin Exp Ophthalmol,2018,256(1)49-58.
[14]PAUL MITCHELL,TIEH YIN WONG.Management Paradigms for Diabetic Macular Edema[J].American Journal Of phthalmology,2014,157(3):505-513.
[15]李波,李传课.李传课教授的内障之水肿论[J].中国中医眼科杂志,2015,25(3):172-174.
[16]朱晶,吴超琼,鲁铭,等.中药联合玻璃体腔内注射雷珠单抗治疗糖尿病性黄斑水肿的疗效观察[J].南京中医药大学学报,2015,3(4):327-330.
[17]刘雪.糖尿病性黄斑水肿的眼科影像学特征及其中医证型相关研究[D].广州:广州中医药大学.2010.
[18]庞凤,刘国军.益气活血利湿汤联合雷珠单抗玻璃体腔注射对糖尿病性黄斑水肿的疗效观察[J].中国中医眼科杂志,2017,27(4):246-249.
[19]陶荣三,陈梦平,荆文涛.中西医结合治疗糖尿病性黄斑水肿临床研究[J].中医学报,2017,32(9):1633-1636.
[20]王家良.芪明颗粒联合激光治疗糖尿病黄斑水肿临床观察[J].实用中医药杂志,2015,3(12):1093-1094.
[21]肖强.芪明颗粒联合雷珠单抗治疗糖尿病性黄斑水肿的临床研究[J].现代药物与临床,2017,3(2):296-299
[22]殷莉,张德龙,任骞,等.芪明颗粒辅助雷珠单抗治疗糖尿病性黄斑水肿的临床疗效观察[J].世界临床药物,2016,37(11):735-739.
[23]宋莉,金伟孝,郑瑜,等.益气聪明汤加味联合雷珠单抗治疗糖尿病黄斑水肿的临床观察[J].中国中医眼科杂志,2017,27(6):355-359.
[24]CUGATI S,WANG JJ,ROCHTCHINA E,et al.Ten-year incidence of retinal vein occlusion in an older population:the Blue Mountains Eye Study[J].Rochtchina EArch Ophthalmol.2006,124(5):726-32.
[25]宫俊芳,王晓莉,孙涛,等.疏血通联合玻璃体腔内注射雷珠单抗和激光光凝治疗BRVO伴黄斑水肿[J].国际眼科杂志,2017,17(11):2112-2115.
[26]陆秉文,吴星伟.中医药干预治疗视网膜静脉阻塞并发黄斑水肿的疗效观察[J].中国中医眼科杂志,2013,23(5):328-332.
[27]冯亚兰,吴星伟.雷珠单抗玻璃体腔注射联合复方丹参静脉滴注治疗视网膜分支静脉阻塞引起的黄斑水肿疗效分析[J].中国中医眼科杂志,2015,25(2):107-110.
[28]陶荣三,陈梦平,荆文涛.中药联合雷珠单抗玻璃体腔注射治疗视网膜静脉阻塞性黄斑水肿的疗效观察[J].医药论坛杂志,2017,38(1):148-150.
[29]姚月蓉,王晗敏,朱蓓菁,等.中药联合雷珠单抗及激光治疗视网膜静脉阻塞性黄斑水肿的临床观察[J].中国中医眼科杂志,2017,27(1):24-27.
[2]BURAK SIMSEK,AYLIN ARDAGIL AKCAKAYA,ISILAY,et al.Long-term outcomes of Ranibizumab treatment in neovascular agerelated macular degeneration[J].Int Eye Sci,2018,18(3):406-411.
[3]罗丹.黄斑变性1号方治疗渗出型年龄相关性黄斑变性的临床观察及机制研究[D].北京:北京中医药大学,2017.
[4]吴权龙,彭清华,陈向东,等.散血明目片联合雷珠单抗眼内注射治疗湿性年龄相关性黄斑变性的临床观察[J].中南药学,2016,14(3):329-332.
[5]贺凤娇,谢文军,姜尚平.益气复明汤联合雷珠单抗治疗渗出型老年性黄斑变性60例总结[J],湖南中医杂志,2017,33(10):81-83.
[6]WONG TY,FERREIRA A,HUGHES R,et al.Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization:an evidence-based systematic review[J].American Journal of Ophthalmology,2014,157(1):9-25.
[7]张红,庄曾渊.高度近视黄斑出血荧光素眼底血管造影改变与辨证论治关系的初步研究[J].中国中医眼科杂志,2007,17(4):192-196.
[8]刘彦江,张月,亢泽峰,等.加减驻景方联合雷珠单抗治疗高度近视性黄斑出血[J].国际眼科杂志,2014,14(2):313-316.
[9]刘莉,张凤梅,李昊洋.中西医结合治疗高度近视黄斑出血临床观察[J].实用中医药杂志,2017,33(12):1397-1398.
[10]闫亚红.中西医结合治疗高度近视黄斑出血临床分析[C]//江西省第十三次中西医结合中医眼科学术交流会暨赣州市医学会眼科学会第八次学术会议论文汇编,赣州:2006:15.
[11]任征,钟良玉.中药为主治疗中心性渗出性脉络膜视网膜病变[J].中国中医眼科杂志,2003,13(1):43-44.
[12]张丽,孟凡毅,朱珂珂,等.玻璃体腔注射雷珠单抗联合复方血栓通胶囊治疗中心性渗出性脉络膜视网膜病变[J].国际眼科杂志,2017,17(4):706-709.
[13]SONJA G.KARST,JAN LAMMER,CHRISTOPH MITSCH,et al.Detailed analysis of retinal morphology in patients with diabetic macular edema(DME)randomized to ranibizumab or triamcinolone treatment[J].Graefes Arch Clin Exp Ophthalmol,2018,256(1)49-58.
[14]PAUL MITCHELL,TIEH YIN WONG.Management Paradigms for Diabetic Macular Edema[J].American Journal Of phthalmology,2014,157(3):505-513.
[15]李波,李传课.李传课教授的内障之水肿论[J].中国中医眼科杂志,2015,25(3):172-174.
[16]朱晶,吴超琼,鲁铭,等.中药联合玻璃体腔内注射雷珠单抗治疗糖尿病性黄斑水肿的疗效观察[J].南京中医药大学学报,2015,3(4):327-330.
[17]刘雪.糖尿病性黄斑水肿的眼科影像学特征及其中医证型相关研究[D].广州:广州中医药大学.2010.
[18]庞凤,刘国军.益气活血利湿汤联合雷珠单抗玻璃体腔注射对糖尿病性黄斑水肿的疗效观察[J].中国中医眼科杂志,2017,27(4):246-249.
[19]陶荣三,陈梦平,荆文涛.中西医结合治疗糖尿病性黄斑水肿临床研究[J].中医学报,2017,32(9):1633-1636.
[20]王家良.芪明颗粒联合激光治疗糖尿病黄斑水肿临床观察[J].实用中医药杂志,2015,3(12):1093-1094.
[21]肖强.芪明颗粒联合雷珠单抗治疗糖尿病性黄斑水肿的临床研究[J].现代药物与临床,2017,3(2):296-299
[22]殷莉,张德龙,任骞,等.芪明颗粒辅助雷珠单抗治疗糖尿病性黄斑水肿的临床疗效观察[J].世界临床药物,2016,37(11):735-739.
[23]宋莉,金伟孝,郑瑜,等.益气聪明汤加味联合雷珠单抗治疗糖尿病黄斑水肿的临床观察[J].中国中医眼科杂志,2017,27(6):355-359.
[24]CUGATI S,WANG JJ,ROCHTCHINA E,et al.Ten-year incidence of retinal vein occlusion in an older population:the Blue Mountains Eye Study[J].Rochtchina EArch Ophthalmol.2006,124(5):726-32.
[25]宫俊芳,王晓莉,孙涛,等.疏血通联合玻璃体腔内注射雷珠单抗和激光光凝治疗BRVO伴黄斑水肿[J].国际眼科杂志,2017,17(11):2112-2115.
[26]陆秉文,吴星伟.中医药干预治疗视网膜静脉阻塞并发黄斑水肿的疗效观察[J].中国中医眼科杂志,2013,23(5):328-332.
[27]冯亚兰,吴星伟.雷珠单抗玻璃体腔注射联合复方丹参静脉滴注治疗视网膜分支静脉阻塞引起的黄斑水肿疗效分析[J].中国中医眼科杂志,2015,25(2):107-110.
[28]陶荣三,陈梦平,荆文涛.中药联合雷珠单抗玻璃体腔注射治疗视网膜静脉阻塞性黄斑水肿的疗效观察[J].医药论坛杂志,2017,38(1):148-150.
[29]姚月蓉,王晗敏,朱蓓菁,等.中药联合雷珠单抗及激光治疗视网膜静脉阻塞性黄斑水肿的临床观察[J].中国中医眼科杂志,2017,27(1):24-27.